EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results

Yoshiya Tanaka iD, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, Bernard G Combe, Alan J Kivitz, Sang-Cheol Bae, Edward C Keystone, Peter Nash und 9 weitere

Modern Rheumatology · 2023

DOI: 10.1093/mr/roac084 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Yoshiya Tanaka und 20 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Janus Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To present safety and efficacy of the JAK1 preferential inhibitor filgotinib in Japanese patients with prior inadequate response (IR) to methotrexate (MTX) from a 52-week randomised controlled parent study (PS) and long-term extension (LTE) through June 2020.

Methods

The PS (NCT02889796) randomised MTX-IR patients to filgotinib 200 (FIL200) or 100 mg (FIL100), adalimumab (ADA) 40 mg, or placebo; all took stable background MTX. At week (W) 24, placebo patients were rerandomised to FIL200 or FIL100. The primary endpoint was W12 American College of Rheumatology 20% improvement; safety was assessed by adverse event (AE) reporting. For the LTE (NCT03025308), eligible filgotinib patients continued FIL200/FIL100; ADA patients were rerandomised (blinded) to FIL200 or FIL100; all continued MTX.

Results

In all, 114/147 Japanese patients completed the PS, 115 enrolled in LTE, and 103 remained on study in June 2020. In the PS, AEs were consistent with the overall population, and W24 efficacy was maintained or improved through W52, comparable with the overall population. LTE AE incidences were similar between doses; filgotinib efficacy was consistent from baseline to W48 and similar between PS ADA and filgotinib patients.

Conclusions

Among MTX-IR Japanese patients, filgotinib maintained efficacy over 1 year; LTE safety was consistent with the PS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidJanus Kinase InhibitorsAnimalsHumansAdalimumabDouble-Blind MethodDrug Therapy, CombinationEast Asian PeopleJanus Kinase 1MethotrexateTreatment OutcomePyridinesTriazoles

Stichwörter der Autor:innen

Filgotiniblong-term follow-uprheumatoid arthritissafety

Substanzen

AdalimumabAntirheumatic AgentsJanus Kinase 1Janus Kinase InhibitorsMethotrexateGLPG0634PyridinesTriazoles

Autor:innen und Institutionen

  • First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
  • Department of Orthopedics, Matsubara Mayflower Hospital, Kato, Hyogo, Japan.
  • Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
  • Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.
  • Aichi Developmental Disability Center, Kasugai, Aichi, Japan.
  • Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.

ORCID-Profile: Yoshiya Tanaka

Zitieren

APA

Tanaka, Y., Matsubara, T., Atsumi, T., Amano, K., Ishiguro, N., Sugiyama, E., Yamaoka, K., Combe, B. G., Kivitz, A. J., Bae, S. C., Keystone, E. C., Nash, P., Genovese, M., Matzkies, F., Bartok, B., Pechonkina, A., Kondo, A., Ye, L., Gong, Q., …, & Takeuchi, T. (2023). Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results. Modern Rheumatology. https://doi.org/10.1093/mr/roac084

Vancouver

Tanaka Y, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, et al. Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results. Modern Rheumatology. 2023. doi:10.1093/mr/roac084

BibTeX
@article{Tanaka2023,
  author = {Tanaka, Yoshiya and Matsubara, Tsukasa and Atsumi, Tatsuya and Amano, Koichi and Ishiguro, Naoki and Sugiyama, Eiji and Yamaoka, Kunihiro and Combe, Bernard G and Kivitz, Alan J and Bae, Sang-Cheol and Keystone, Edward C and Nash, Peter and Genovese, Mark and Matzkies, Franziska and Bartok, Beatrix and Pechonkina, Alena and Kondo, Akira and Ye, Lei and Gong, Qi and Tasset, Chantal and Takeuchi, Tsutomu},
  title = {Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results},
  journal = {Modern Rheumatology},
  year = {2023},
  doi = {10.1093/mr/roac084}
}
Kostenlos starten →